SIGNUP FOR NEWSLETTER

TSX: HSM     NASDAQ: HSDT

Call us: +1 877-564-0008

Menu

Stock Quote - HSM-T

*Delayed quote courtesy of Google.

Stock Quote - HSDT

*Delayed quote courtesy of Google.

2020 News

Filters
List of articles in category 2020 News
Title Date
Helius Medical Technologies, Inc. Submits Request for FDA Clearance for PoNS™ Device; Reports Preliminary Financial Results for the Second Quarter and Six Months Ended June 30, 2020 06 Aug, 2020
Helius Medical Technologies Announces the Dismissal of the Shareholder Class Action Lawsuit 14 Jul, 2020
Helius Medical Technologies to Present at the Virtual Summer Summit on June 9th 05 Jun, 2020
Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis 12 May, 2020
Helius Medical Technologies, Inc. Reports First Quarter of Full Year 2020 Financial Results; Updates Full Year 2020 Outlook 07 May, 2020
UPDATE -- Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBI 30 Apr, 2020
Helius Medical Technologies, Inc. Announces Publication of its PoNS™ Registrational Clinical Trial (TBI-001) in TBI 30 Apr, 2020
Helius Medical Technologies to Release First Quarter of Fiscal Year 2020 Financial Results on May 7, 2020 22 Apr, 2020
Helius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of Directors 22 Apr, 2020
Helius Medical Technologies Announces Authorization from Health Canada to Market the PoNS™ Device for the Treatment of Gait Deficit Due to Mild and Moderate Multiple Sclerosis (MS) 24 Mar, 2020
Helius Medical Technologies Announces $2.2 Million Registered Direct Offering 18 Mar, 2020
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results; Introduces Full Year 2020 Outlook 12 Mar, 2020
Helius Medical Technologies, Inc. Provides Details on Five Recently Authorized PoNS Treatment™ Clinics 09 Mar, 2020
Helius Medical Technologies Reports Preliminary Unaudited Fourth Quarter and Full Year Unaudited 2019 Financial Results, Provides Commercial and Regulatory Update and Announces Submission to Health Canada for Multiple Sclerosis (MS) Label Expansion and New US Regulatory Prioritization for MS 02 Mar, 2020
Helius Medical Technologies CEO Philippe Deschamps to Deliver Congressional Briefing on the Latest Technologies, Innovations and Policies in Clinical Neuroscience 24 Feb, 2020
Helius Medical Technologies Inc. Welcomes Cline Medical Centre as an Authorized PoNS Treatment™ Clinic in Nanaimo, BC 07 Feb, 2020
Helius Medical Technologies to Release Fourth Quarter and Fiscal Year 2019 Financial Results on March 12, 2020 05 Feb, 2020
Helius Medical Technologies, Inc. Issues a Clarification to the News Release Regarding the Agreement with the University Health Network (UHN) Issued at 7:05 am January 16, 2020 16 Jan, 2020
Helius Medical Technologies, Inc. and University Health Network (UHN) Have Signed an Agreement for UHN and three Neuro-Rehabilitation Centers to Perform a Clinical Experience Program of the PoNS™ Device in Canada 16 Jan, 2020
Helius Medical Technologies Awarded Pioneer Technology Development Award 10 Jan, 2020
Independent Research Published Show Positive Results on Translingual Neurostimulation Plus Physical Therapy With Statistically Significant Improvement in Balance and Gait Scores and the Outcomes Were Sustained for 12 Weeks After Discontinuing Treatment 19 Dec, 2019